Posted by Michael Wonder on 10 Jul 2024
Aplidin will be re-evaluated by the EMA. The European Commission revokes the decision that initially denied PharmaMar's marketing authorisation for multiple myeloma due to a conflict of interest.
8 July 2024 - The European Commission has acknowledged that an expert from the Scientific Advisory Group, who was developing a rival product was allowed to participate in the marketing authorisation procedure for Aplidin (plitidepsin).
PharmaMar has received a notification from the European Commission informing the Company of its decision to revoke the refusal to grant marketing authorisation for Aplidin in multiple myeloma.
